Experience of Bedaquiline use in treatment of XDR-TB patients Source: International Congress 2017 – TB: diagnosis, severity and practical management Year: 2017
Effectiveness and safety of meropenem/clavulanate-containing regimens in the treatment of MDR- and XDR-TB Source: Eur Respir J 2016; 47: 1235-1243 Year: 2016
Evaluation of failures treated with linezolid-containing regimen for extensively drug-resistant tuberculosis (XDR-TB) Source: International Congress 2015 – TB treatment: new drugs and drug resistance Year: 2015
Effectiveness and safety of six month chemotherapy course of XDR TB including bedaquiline and linezolid Source: International Congress 2016 – Rifampicin resistance, MDRTB, and new drug treatments Year: 2016
Treatment options for MDR- and XDR-TB Source: Eur Respir Monogr 2017; 75: 232-244 Year: 2017
Linezolid in the treatment of patients with MDR TB and XDR TB Source: Annual Congress 2013 –Drug-resistant tuberculosis Year: 2013
Treatment of MDR-TB Source: International Congress 2015 – CC1 Diagnosis and management of MDR-TB Year: 2015
Efficacy of intravenous administration of anti-tuberculosis drugs in patients with multidrug-resistant tuberculosis Source: Annual Congress 2013 –Drug-resistant tuberculosis Year: 2013
MDR-TB and XDR-TB: drug resistance and treatment outcomes Source: Eur Respir J 2009; 34: 778 Year: 2009
Efficiency of MDR-TB therapy with the use of thioureidoiminomethylpyridinii perchlorate Source: International Congress 2016 – Rifampicin resistance, MDRTB, and new drug treatments Year: 2016
Effectiveness of the WHO regimen for treatment of multidrug resistant tuberculosis (MDR-TB) Source: Annual Congress 2013 –Drug-resistant tuberculosis: new clinical and public health insights Year: 2013
Effectiveness and safety of imipenem/clavulanate- versus meropenem/clavulanate-containing regimens in the treatment of multidrug resistant tuberculosis Source: International Congress 2016 – Rifampicin resistance, MDRTB, and new drug treatments Year: 2016
Bedaquiline-containing regimens for MDR TB treatment – Focus on the safety Source: International Congress 2016 – Drug-resistant tuberculosis and experiences with delamanid and bedaquiline Year: 2016
Clinical experience of clofazimine in the treatment of MDR-TB Source: Annual Congress 2013 –Drug-resistant tuberculosis Year: 2013
Early outcomes in MDR-TB and XDR-TB patients treated with delamanid under compassionate use Source: Eur Respir J, 50 (1) 1700311; 10.1183/13993003.00311-2017 Year: 2017
Impact of XDR-TB on treatment outcome of MDR-TB patients with standardized regimens Source: Annual Congress 2008 - The challenge of multidrug-resistant tuberculosis Year: 2008
Association of anti-tuberculosis drug concentrations in hair and treatment outcomes in MDR- and XDR-TB Source: ERJ Open Res, 5 (2) 00046-2019; 10.1183/23120541.00046-2019 Year: 2019
Administration of linezolid, bedaquiline and imipenem in treatment of patients with extensively drug-resistant tuberculosis Source: International Congress 2015 – TB treatment: new drugs and drug resistance Year: 2015
Novel drug regimens against MDR-TB Source: International Congress 2016 – The problem of multidrug-resistant tuberculosis Year: 2016
Evaluation of co-trimoxazole in the treatment of multidrug-resistant tuberculosis Source: Eur Respir J 2013; 42: 504-512 Year: 2013